Top

Published in:

Open Access 01-12-2024 | Research

Correlation of DNA methylation of DNMT3A and TET2 with oral squamous cell carcinoma

Authors: Xueming Li, Zaikun Li, Qingxi Gao, Yanan Peng, Yang Yu, Tenglong Hu, Wei Wang

Published in: Discover Oncology | Issue 1/2024

Abstract

Oral squamous cell carcinoma (OSCC) is the sixth most common malignancy worldwide. Abnormal epigenetic modifications, including DNA methylation, are hallmarks of cancer and implicated in the development of various tumors. DNA methylation is catalyzed by the DNA methyltransferase and ten-eleven translocation dioxygenase families, with DNMT3A and TET2 being the most widely studied members, respectively. The correlation of methylation β values and clinical features was conducted in patients with OSCC in The Cancer Genome Atlas database. DNA methylation and protein expression levels of DNMT3A and TET2 in tissues were analyzed with methylation-specific polymerase chain reaction (MSP) and western blotting. To evaluate the effects of DNMT3A and TET2 on the biological characteristics of OSCC, cell proliferation was assessed with 5-ethynyl-2'-deoxyuridine, and cell migration capacity was quantified with wound healing and transwell assays. A survival analysis was performed with the Kaplan–Meier approach. The correlation between different methylation β values and clinical features was revealed. MSP revealed varying methylation degrees of DNMT3A and TET2 in OSCC tissues. Furthermore, western blotting showed that the protein expression levels were significantly different in cancer and surrounding healthy tissue samples. In vitro experiments demonstrated that DNMT3A knockdown and TET2 overexpression could inhibit the proliferation and migration of OSCC. Survival analysis revealed that patients with high DNMT3A methylation levels showed higher survival rates.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–12.PubMedCrossRef

Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150:12–22.PubMedCrossRef

Kulis M, Esteller M. DNA methylation and cancer. Adv Genet. 2010;70:27–35.PubMedCrossRef

Qiu M, Zhang N, Yao S, Zhou H, Chen X, Jia Y, et al. DNMT3A-mediated high expression of circ_0057504 promotes benzo[a]pyrene-induced DNA damage via the NONO-SFPQ complex in human bronchial epithelial cells. Environ Int. 2022. https://doi.org/10.1016/j.envint.2022.107627.CrossRefPubMedPubMedCentral

Bondarev N, Ivanenko K, Khabusheva E, Lebedev T, Manukhov I, Prassolov V. MGL S3 chimeric enzyme drives apoptotic death of EGFR-dependent cancer cells through ERK downregulation. Int J Mol Sci. 2022;23:12807.PubMedPubMedCentralCrossRef

Li Y, Gan Y, Liu J, Li J, Zhou Z, Tian R, et al. Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer. Signal Transduct Target Ther. 2022;7:87.PubMedPubMedCentralCrossRef

Liang Y, Cen J, Huang Y, Fang Y, Wang Y, Shu G, et al. CircNTNG1 inhibits renal cell carcinoma progression via HOXA5-mediated epigenetic silencing of Slug. Mol Cancer. 2022;21:224.PubMedPubMedCentralCrossRef

He J, Dong C, Zhang H, Jiang Y, Liu T, Man X. The oncogenic role of TFAP2A in bladder urothelial carcinoma via a novel long noncoding RNA TPRG1-AS1/DNMT3A/CRTAC1 axis. Cell Signal. 2023;102:110527.PubMedCrossRef

Lu W, Lu T, Wei X. Downregulation of DNMT3a expression increases miR-182-induced apoptosis of ovarian cancer through caspase-3 and caspase-9-mediated apoptosis and DNA damage response. Oncol Rep. 2016;36:3597–603.PubMedCrossRef

10.

Li S, Hu J, Li G, Mai H, Gao Y, Liang B, et al. Epigenetic regulation of LINC01270 in breast cancer progression by mediating LAMA2 promoter methylation and MAPK signaling pathway. Cell Biol Toxicol. 2022. https://doi.org/10.1007/s10565-022-09763-9.CrossRefPubMedPubMedCentral

11.

Zhou Y, Yang Z, Zhang H, Li H, Zhang M, Wang H, et al. DNMT3A facilitates colorectal cancer progression via regulating DAB2IP mediated MEK/ERK activation. Biochim Biophys Acta Mol Basis Dis. 2022;1868:166353.PubMedCrossRef

12.

Zhao Z, Song J, Tang B, Fang S, Zhang D, Zheng L, et al. CircSOD2 induced epigenetic alteration drives hepatocellular carcinoma progression through activating JAK2/STAT3 signaling pathway. J Exp Clin Cancer Res. 2020;39:259.PubMedPubMedCentralCrossRef

13.

Quivoron C, Couronné L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011;20:25–33.PubMedCrossRef

14.

Álvarez-Errico D, Vento-Tormo R, Sieweke M, Ballestar E. Epigenetic control of myeloid cell differentiation, identity and function. Nat Rev Immunol. 2015;15:7–1.PubMedCrossRef

15.

Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360:2289–92.PubMedCrossRef

16.

Ma S, Wan X, Deng Z, Shi L, Hao C, Zhou Z, et al. Epigenetic regulator CXXC5 recruits DNA demethylase Tet2 to regulate TLR7/9-elicited IFN response in pDCs. J Exp Med. 2017;214:1471–81.PubMedPubMedCentralCrossRef

17.

Zhang Q, Zhao K, Shen Q, Han Y, Gu Y, Li X, et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature. 2015;525:389–93.PubMedPubMedCentralCrossRef

18.

Cull AH, Snetsinger B, Buckstein R, Wells RA, Rauh MJ. Tet2 restrains inflammatory gene expression in macrophages. Exp Hematol. 2017;55:56–7.PubMedCrossRef

19.

Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355:842–8.PubMedPubMedCentralCrossRef

20.

Deng W, Wang J, Zhang J, Cai J, Bai Z, Zhang Z. TET2 regulates LncRNA-ANRIL expression and inhibits the growth of human gastric cancer cells. IUBMB Life. 2016;68:355–63.PubMedCrossRef

21.

Nickerson ML, Das S, Im KM, Turan S, Berndt SI, Li H, et al. TET2 binds the androgen receptor and loss is associated with prostate cancer. Oncogene. 2017;36:2172–82.PubMedCrossRef

22.

Alrehaili AA, Gharib AF, Alghamdi SA, Alhazmi A, Al-Shehri SS, Hagag HM, et al. Evaluation of TET family gene expression and 5-hydroxymethylcytosine as potential epigenetic markers in non-small cell lung cancer. In Vivo. 2023;37:445–54.PubMedPubMedCentralCrossRef

23.

Lyu R, Zhu X, Shen Y, Xiong L, Liu L, Liu H, et al. Tumour suppressor TET2 safeguards enhancers from aberrant DNA methylation and epigenetic reprogramming in ERα-positive breast cancer cells. Epigenetics. 2022;17:1180–1.PubMedCrossRef

24.

Lopez-Bertoni H, Johnson A, Rui Y, Lal B, Sall S, Malloy M, et al. Sox2 induces glioblastoma cell stemness and tumor propagation by repressing TET2 and deregulating 5hmC and 5mC DNA modifications. Signal Transduct Target Ther. 2022;7:37.PubMedPubMedCentralCrossRef

25.

Gong F, Guo Y, Niu Y, Jin J, Zhang X, Shi X, et al. Epigenetic silencing of TET2 and TET3 induces an EMT-like process in melanoma. Oncotarget. 2017;8:315–23.PubMedCrossRef

26.

Adhikari BR, Uehara O, Matsuoka H, Takai R, Harada F, Utsunomiya M, et al. Immunohistochemical evaluation of Klotho and DNA methyltransferase 3a in oral squamous cell carcinomas. Med Mol Morphol. 2017;50:155–61.PubMedCrossRef

27.

Yakushiji T, Uzawa K, Shibahara T, Noma H, Tanzawa H. Over-expression of DNA methyltransferases and CDKN2A gene methylation status in squamous cell carcinoma of the oral cavity. Int J Oncol. 2003;22:1201–11.PubMed

28.

Daniel FI, Rivero ER, Modolo F, Lopes TG, Salum FG. Immunohistochemical expression of DNA methyltransferases 1, 3a and 3b in oral leukoplakias and squamous cell carcinomas. Arch Oral Biol. 2010;55:1024–31.PubMedCrossRef

29.

Supic G, Kozomara R, Zeljic K, Jovic N, Magic Z. Prognostic value of the DNMTs mRNA expression and genetic polymorphisms on the clinical outcome in oral cancer patients. Clin Oral Invest. 2017;21:173–81.CrossRef

30.

Jäwert F, Hasséus B, Kjeller G, Magnusson B, Sand L, Larsson L. Loss of 5-hydroxymethylcytosine and TET2 in oral squamous cell carcinoma. Anticancer Res. 2013;33:4325–34.PubMed

31.

Wang X, Zhang Y, Sun L, Wang S, Nie J, Zhao W, et al. Evaluation of the clinical application of multiple tumor marker protein chip in the diagnostic of lung cancer. J Clin Lab Anal. 2018;32:e22565.PubMedPubMedCentralCrossRef

32.

Werner RJ, Kelly AD, Issa JJ. Epigenetics and precision oncology. Cancer J. 2017;23:262–72.PubMedPubMedCentralCrossRef

33.

Yu J, Ge Z, Chen S, Li S, Zhang X, Hu J, et al. miR-26a-5p suppresses Wnt/β-catenin signaling pathway by inhibiting DNMT3A-mediated SFRP1 methylation and inhibits cancer stem cell-like properties of NSCLC. Dis Markers. 2022;2022:7926483.PubMedPubMedCentralCrossRef

34.

Lu J, Zhen S, Tuo X, Chang S, Yang X, Zhou Y, et al. Downregulation of DNMT3A attenuates the warburg effect, proliferation, and invasion via promoting the inhibition of miR-603 on HK2 in ovarian cancer. Technol Cancer Res Treat. 2022. https://doi.org/10.1177/15330338221110668.CrossRefPubMedPubMedCentral

35.

Pang Y, Liu J, Li X, Xiao G, Wang H, Yang G, et al. MYC and DNMT3A-mediated DNA methylation represses microRNA-200b in triple negative breast cancer. J Cell Mol Med. 2018;22:6262–6.PubMedPubMedCentralCrossRef

36.

Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002;21:5427–35.PubMedCrossRef

37.

Hitchins MP, Ward RL. Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. J Med Genet. 2009;46:793–8.PubMedCrossRef

38.

Casalino L, Verde P. Multifaceted roles of DNA methylation in neoplastic transformation, from tumor suppressors to EMT and metastasis. Genes. 2020;11:922.PubMedPubMedCentralCrossRef

39.

Markou Α, Londra D, Tserpeli V, Kollias Ι, Tsaroucha E, Vamvakaris I, et al. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection. Clin Epigenet. 2022;14:61.CrossRef

40.

Subramaniam D, Thombre R, Dhar A, Anant S. DNA methyltransferases: a novel target for prevention and therapy. Front Oncol. 2014;4:80.PubMedPubMedCentralCrossRef

41.

Lian H, Li WB, Jin WL. The emerging insights into catalytic or non-catalytic roles of TET proteins in tumors and neural development. Oncotarget. 2016;7:64512–6.PubMedPubMedCentralCrossRef

42.

Rasmussen KD, Helin K. Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev. 2016;30:733–7.PubMedPubMedCentralCrossRef

43.

El-Harakeh M, Saliba J, SharafAldeen K, Haidar M, El Hajjar L, Awad MK, et al. Expression of the methylcytosine dioxygenase ten-eleven translocation-2 and connexin 43 in inflammatory bowel disease and colorectal cancer. World J Gastroenterol. 2022;28:5845–55.PubMedPubMedCentralCrossRef

44.

Gao J, Liu R, Feng D, Huang W, Huo M, Zhang J, et al. Snail/PRMT5/NuRD complex contributes to DNA hypermethylation in cervical cancer by TET1 inhibition. Cell Death Differ. 2021;28:2818–22.PubMedPubMedCentralCrossRef

45.

Fujikura K, Alruwaii ZI, Haffner MC, Trujillo MA, Roberts NJ, Hong SM, et al. Downregulation of 5-hydroxymethylcytosine is an early event in pancreatic tumorigenesis. J Pathol. 2021;254:279–82.PubMedPubMedCentralCrossRef

Title: Correlation of DNA methylation of DNMT3A and TET2 with oral squamous cell carcinoma
Authors: Xueming Li
Zaikun Li
Qingxi Gao
Yanan Peng
Yang Yu
Tenglong Hu
Wei Wang
Publication date: 01-12-2024
Publisher: Springer US
Published in: Discover Oncology / Issue 1/2024
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-024-00866-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

The endoplasmic reticulum stress-related genes and molecular typing predicts prognosis and reveals characterization of tumor immune microenvironment in lung squamous cell carcinoma

Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma

Feasibility analysis of arterial CT radiomics model to predict the risk of local and metastatic recurrence after radical cystectomy for bladder cancer

Novel insights into the roles of migrasome in cancer

Mechanism of regulation of KIF23 on endometrial cancer cell growth and apoptosis

A rare case report: multiple intrahepatic masses in a pediatric patient with citrin deficiency

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials